Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

Employers are projecting a median 10% increase in healthcare costs for 2026, driven largely by high claims and specialty drug ...

Hospital margins improved in June as revenue gains outpaced patient volume — but Kaufman Hall’s latest data shows that financial gaps between high- and low-performing organizations persist, with ...

Employers expect healthcare costs to rise by a median of 9% in 2026, according to a survey by the Business Group on Health. Pharmacy expenses are a key driver.

As healthcare organizations experiment with AI, they're learning more about the technology as they generate evidence that these tools improve efficiency and reduce costs.

Even with venture capital fundraising slowing down, Hatteras Venture Partners was able to close two new funds for investments in seed- and early-stage companies. We also have a recap of recent ...

Pfizer’s inclacumab did not beat a placebo in a Phase 3 test in sickle cell disease. The trial failure comes nearly a year after Pfizer voluntarily withdrew Oxbryta from the market after tests ...

In today’s healthcare landscape, credibility doesn’t come from an agency logo. It comes from an idea that lands, a brand platform that manifests quickly, and results that speak for themselves.

Some large health systems are experimenting with selling their internal capabilities — such as IT support, revenue cycle management and call center operations — to smaller hospitals as a new ...